DelMar Pharmaceuticals, Inc. Uncategorized Contracts & Agreements

31 Contracts & Agreements
Recent Contracts
Category
Company
Industry
Jur. Jurisdiction
Filed
Contingent Value Rights Agreement, dated October 18, 2024, by and between TuHURA Biosciences, Inc. (f/k/a Kintara Therapeutics, Inc.) and Equiniti Trust Company, LLC
DelMar Pharmaceuticals, Inc.
Biotechnology
2025
Form of Lock-Up Agreement
DelMar Pharmaceuticals, Inc.
Biotechnology
2024
Form of Kineta Support Agreement
DelMar Pharmaceuticals, Inc.
Biotechnology
DE
2024
Form of TuHURA Support Agreement
DelMar Pharmaceuticals, Inc.
Biotechnology
DE
2024
CTF Agreement, dated December 11, 2024, by and between TuHURA and Kineta
DelMar Pharmaceuticals, Inc.
Biotechnology
DE
2024
Form of Option Agreement under the Amended and Restated Equity Plan of Morphogenesis, Inc
DelMar Pharmaceuticals, Inc.
Biotechnology
FL
2024
Amended and Restated Equity Plan of Morphogenesis, Inc
DelMar Pharmaceuticals, Inc.
Biotechnology
FL
2024
Form of Lock-Up Agreement
DelMar Pharmaceuticals, Inc.
Biotechnology
2024
Form of TuHURA Support Agreement
DelMar Pharmaceuticals, Inc.
Biotechnology
DE
2024
Form of Contingent Value Rights Agreement
DelMar Pharmaceuticals, Inc.
Biotechnology
DE
2024
Form of Kintara Support Agreement
DelMar Pharmaceuticals, Inc.
Biotechnology
DE
2024
Engagement Agreement, dated September 10, 2021
DelMar Pharmaceuticals, Inc.
Biotechnology
NY
2021
Description of Securities
DelMar Pharmaceuticals, Inc.
Biotechnology
2020
Form of Adgero Support Agreement
DelMar Pharmaceuticals, Inc.
Biotechnology
DE
2020
Form of DelMar Support Agreement
DelMar Pharmaceuticals, Inc.
Biotechnology
DE
2020
Form of Adgero Support Agreement
DelMar Pharmaceuticals, Inc.
Biotechnology
DE
2020
Form of DelMar Support Agreement
DelMar Pharmaceuticals, Inc.
Biotechnology
DE
2020
Form of Leak-Out Agreement, dated as of August 14, 2019
DelMar Pharmaceuticals, Inc.
Biotechnology
2019
Form of Dealer Manager Agreement
DelMar Pharmaceuticals, Inc.
Biotechnology
NY
2019
Form of Leak-Out Agreement, dated as of November 25, 2018, by and between DelMar Pharmaceuticals, Inc. and the Exercising Holders
DelMar Pharmaceuticals, Inc.
Biotechnology
2018
Agreement, effective as of November 3, 2017 between the Company and Mr. Zarrabian
DelMar Pharmaceuticals, Inc.
Biotechnology
2017
Engagement Letter, dated September 17, 2017 between DelMar Pharmaceuticals, Inc. and H.C. Wainwright & Co., LLC
DelMar Pharmaceuticals, Inc.
Biotechnology
NY
2017
430 Park Avenue| New York, New York 10022 | 212 ###-###-#### | www.hcwco.com Member: FINRA/SIPC
DelMar Pharmaceuticals, Inc.
Biotechnology
NY
2017
SECURITIESPURCHASE AGREEMENT
DelMar Pharmaceuticals, Inc.
Biotechnology
NY
2017
EXECUTIVEEMPLOYMENT AGREEMENT
DelMar Pharmaceuticals, Inc.
Biotechnology
2017
EXECUTIVEEMPLOYMENT AGREEMENT
DelMar Pharmaceuticals, Inc.
Biotechnology
2017
DELMAR PHARMACEUTICALS, INC. ROYALTYAGREEMENT
DelMar Pharmaceuticals, Inc.
Biotechnology
NY
2016
DELMARPHARMACEUTICALS, INC. SECURITIESPURCHASE AGREEMENT
DelMar Pharmaceuticals, Inc.
Biotechnology
NY
2016
DELMAR PHARMACEUTICALS, INC. AUDIT COMMITTEE CHARTER A. Purpose and Scope
DelMar Pharmaceuticals, Inc.
Biotechnology
2015
U.S.SUBSCRIPTION AGREEMENT
DelMar Pharmaceuticals, Inc.
Biotechnology
NY
2015
ESCROWAGREEMENT (PUBLIC OFFERING)
DelMar Pharmaceuticals, Inc.
Biotechnology
NY
2015